Global Bioresorbable Coronary Scaffolds Market Trends, Forecast Report 2025-2037
Bioresorbable Coronary Scaffolds Market size is projected to grow from USD 650.4 million to USD 3.1 billion, witnessing a CAGR of over 18.7% during the forecast period, between 2025 and 2037. In 2025, the industry size of bioresorbable coronary scaffolds is estimated at USD 750.1 million.
The rising cases of cardiovascular disorder (CVD) are becoming a serious health issue around the world, propelling demand in the bioresorbable coronary scaffolds market. In this regard, the WHO reported that more than 523.4 million incidences of this ailment were recorded in 2024, globally. Other data published by the Centers for Disease Control and Prevention (CDC) calculated a 45.1% of net CVD-associated surgeries, originated from coronary artery disease (CAD), to escalate the surge in bioresorbable solutions in 2023. Additionally, in 2025, Germany alone presented a 1.3 million consumer base, afflicted with peripheral artery disease (PAD), which received treatment with scaffolds. This demography reflects the multi-discipline application and sustainable cash inflow for offerings from this sector.
Various factors with economic uncertainty, such as production cost, expenses on material outsourcing, and variability in trade policies, have shown considerable impact on the payers' pricing structure in the bioresorbable coronary scaffolds market. For instance, in 2024, the volatilities in the expenditure on high-precision manufacturing of both polymer and metal-based components raised the producer price index (PPI) in this sector by 6.3% year-over-year (YoY). As a subsequent result, the consumer price index (CPI) for cardiac implants grew by a yearly 4.9% growth rate in the same year. This represents a possible inflation in both parties, including the manufacturers and payers. Currently, the upgradation in the cost standards for regulated suppliers is positively improving the flow in the supply chain.
Bioresorbable Coronary Scaffolds Market: Growth Drivers and Challenges
Growth Drivers
- Investments in product-related R&D: Both public and private investors are showing interest in upgrading the pipeline of the bioresorbable coronary scaffolds market, creating new business opportunities for global pioneers. For instance, the National Institute of Health (NIH) invested USD 250.2 million in research in this category in 2024, where 45.4% of the total grant was dedicated to polymer-based scaffold innovations. In the same year, the Horizon Europe program in Europe allocated USD 203.6 million to accelerate clinical trials for cutting-edge magnesium-based scaffolds. These efforts to improve the functionality and cost-effectiveness of products available in this sector are also helping associated companies widen their consumer base.
- Tech-based innovations in intervention and production: The integration of advanced technologies in product designing and manufacturing has significantly improved the output in both quality and scalability in the bioresorbable coronary scaffolds market. Particularly, the current trend of factory automation in every industry, specifically in healthcare, is elevating the approach and quantification of produced goods. Additionally, investments in this aspect from several organizations are empowering parallel developments and production capacity in this sector. Following the same methodology, Germany produced 320.3 million worth of polymer precursors every year till 2024 from automated assembly lines.
Historical Patient Growth (2010-2020) and Its Impact on Market Expansion
The bioresorbable coronary scaffolds market underwent a transformative phase during the timeline from 2010 to 2020 due to robust expansion in the patient pool. The significant growth in the afflicted population during this tenure not only fostered a strong foundation but also shaped current dynamics by dragging the focus of global healthcare authorities and investors in this merchandise. Additionally, it constructed a roadmap for current dynamics, trends, and commercial strategies. Moreover, the worldwide spread of rapid aging and high-risk factors, such as obesity, hypertension, and other underlying conditions, propelled this demographic amplification over the past decade.
Historical Patient Growth (2010-2020) in Key Markets
|
Country |
2010 (in Thousand) |
2015 (in Thousand) |
2020 (in Thousand) |
CAGR (2010-2020) |
|
U.S. |
15.3 |
45.2 |
110.3 |
22.4% |
|
Germany |
8.4 |
25.2 |
65.1 |
23.5% |
|
France |
5.1 |
15.1 |
40.1 |
23.4% |
|
Spain |
3.1 |
8.4 |
20.1 |
21.2% |
|
Australia |
2.4 |
6.1 |
15.2 |
22.1% |
|
Japan |
10.2 |
35.1 |
90.5 |
24.4% |
|
India |
1.4 |
4.3 |
12.1 |
28.2% |
|
China |
5.2 |
30.3 |
85.2 |
33.5% |
The strategic alignment with the current dynamics of the bioresorbable coronary scaffolds market helped companies achieve better financial and commercial outcomes. They also set unofficial guidelines, including public-private partnerships (PPPs), product innovation, and resource localization, through their successful operations in this sector. For instance, in 2023, the PPP formation with Apollo Hospitals in India benefitted the field's ecosystem with a 25.4% cost reduction and an 18.2% patient access boost. Additionally, the trend of bulk procurement among end users is also utilized by these leaders as an asset for consumer base expansion and business flow increase. Moreover, these innovative approaches are inspiring and guiding new entrants with a beneficial pathway.
Feasibility Models for Revenue Growth
|
Strategy |
2025 Revenue (USD, million) |
2037 Revenue (USD, million) |
CAGR |
Risk Factor |
|
Premium Pricing (U.S./Europe) |
650.3 |
1,100.2 |
9.5% |
Reimbursement cuts |
|
Cost-Optimized (Asia) |
300.1 |
900.4 |
20.4% |
Local competition |
|
Hybrid Scaffolds |
200.4 |
600.3 |
18.4% |
R&D failure |
Challenge
- Economic hurdles in compliance and insurance: The pricing competency in the bioresorbable coronary scaffolds market is highly prone to be hindered by regulatory and reimbursement volatilities. In this regard, the Centers for Medicare & Medicaid Services revealed that only 60.3% of the scaffold procedures performed across the U.S. were covered by Medicare till 2024. This reflects the gap in accessibility in this field. Additionally, the 18-month extended timeline for MDR clearance in Europe caused an additional USD 5.1 million to the launch budget in 2024. The delay & financial losses in attaining authorized approval and the shortage of adequate financial support accumulatively raise the cost of the final product, making it less accessible for consumers.
Bioresorbable Coronary Scaffolds Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
18.7% |
|
Base Year Market Size (2024) |
USD 650.4 million |
|
Forecast Year Market Size (2037) |
USD 3.1 billion |
|
Regional Scope |
|
Bioresorbable Coronary Scaffolds Segmentation
Material (Polymer-Based, Metal-Based)
Based on the material, the polymer-based segment is expected to dominate the bioresorbable coronary scaffolds market with a share of 68.4% by the end of 2037. The unmatched compatibility of this subtype with living tissues without causing harm is a primary driver in this segment's leadership, as it helps accelerate regulatory approvals and worldwide adoption. Additionally, this material offers several clinical advantages, including reduced risk of complications and high flexibility, which makes it the most preferable option for both CVD surgeons and patients. Moreover, this type of component is also a suitable option for producing affordable solutions on a large scale, bolstering the adoption rate in this segment. Currently, automation in production is bringing a USD 40.4 billion investment for polymer-based scaffolds.
Application (Coronary Artery Disease (CAD), Peripheral Artery Disease (PAD))
In terms of applications, the coronary artery disease (CAD) segment is poised to capture the largest share of 75.3% in the bioresorbable coronary scaffolds market throughout the assessed timeframe. Its proprietorship is majorly attributed to the predominant occurrence of this CVD type, in comparison to PAD. Its higher rate of severity and mortality is also an influential factor in this segment, which secures a significant portion of the net capital influx from concerned organizations. Testifying this, in 2025, the CDC revealed that approximately 45.4% of the total 18.2 million CAD patients across the U.S. require percutaneous coronary intervention every year. As a result, its clinical priority concentrated more than 80.2% of the total reimbursement for CAD-related BCS procedures in this category, solidifying its position for upcoming years.
Our in-depth analysis of the global bioresorbable coronary scaffolds market includes the following segments:
|
Material |
|
|
Application |
|
|
End user |
|
Vishnu Nair
Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Bioresorbable Coronary Scaffolds Industry - Regional Synopsis
North America Market Analysis
North America is predicted to show dominance over the global bioresorbable coronary scaffolds market by garnering the highest revenue share of 40.2% over the analyzed period. The major drivers behind its forefront position are continuously magnifying patient volume and advancing the healthcare system across mature economies, including the U.S. and Canada. In this regard, the CDC reported that the eligibility of CAD patients in North America increased by 40.3% in 2025 from 2018, accounting for 12.4 million. Besides, the ongoing integrations of next-generation technology in CVD interventions, coupled with strong financial support from insurers and for R&D, are empowering the region's global significance as a lucrative landscape in this field.
The U.S. is augmenting leadership in the regional bioresorbable coronary scaffolds market with efforts to strengthen nationwide public access to advanced care. Recent expansions in Medicare coverage and provincial Federal funding are also marking notable contributions to this cohort. For instance, in 2024, the expenditure from Medicare on procedures, incorporating BCS, surpassed USD 1.2 billion, covering more than 70.5% of total interventions performed across the nation. Additionally, the implementation of a reformed reimbursement structure in 2023 resulted in a 25.1% rise in outpatient adoption through ASCs. Moreover, despite the persistent gap in accessibility, the country's efforts to improve such disparity are establishing a strong foundation for this sector.
APAC Market Statistics
The Asia Pacific bioresorbable coronary scaffolds market is estimated to propagate with the highest CAGR in the world by 2037. Its progressive pace of growth is highly fueled by the aging population, increased CVD occurrence & mortality, and government initiatives. For instance, in 2025, the WHO calculated the number of CVD-afflicted citizens across the region to be 45.3 million. Similarly, the Ministry of Health, Labour and Welfare (MHLW) projected the proportion of older citizens, aged 65 and over, in Japan to surpass 33.5% by 2037. This demography further pushes individual governments to reinforce advanced technologies and universal solutions in the cardiac care industry, securing a sustainable consumer base for both domestic and foreign pioneers in this sector.
China is embarking on its leadership in the APAC bioresorbable coronary scaffolds market with its exceptional domestic medical instrument manufacturing and raw material supplying abilities. With an aim to offer comprehensive pricing, the country is highly focused on enhancing the affordability of available products in this field. For instance, the Volume-Based Procurement (VBP) program, commenced by the government of China, successfully reduced cost per unit by 40.3% and increased the number of associated procedures to an annual 50,010 in 2024. Moreover, the nation accomplished 30.4% growth in this sector with support from government-mandated procurement initiatives, consolidating its potential to achieve higher avenues.
Companies Dominating the Bioresorbable Coronary Scaffolds Landscape
The current dynamics of the bioresorbable coronary scaffolds market are significantly controlled by the strategic initiatives and commercial operations of key players. Testifying this, premium pricing, accelerated regulatory approvals, and R&D involvement secured a collective dominance of Abbott, Boston Scientific, and BIOTRONIK in this sector, with a share of 60.4%, in 2024. To achieve this milestone, BIOTRONIK introduced a magnesium-based scaffold in 2024, which further boosted the adoption in this field by 20.1%. Furthermore, in emerging marketplaces, such as India and China, leaders prioritize the scale and cost of production to make their pipeline more competitive against expensive options. This region-specific methodology induces distinct landscapes, broadening the scope of investment in this merchandise.
The top 20 key players in this sector are:
|
Company Name |
Country |
Market Share (2024) |
Industry Focus |
|
Abbott Laboratories |
U.S. |
25.3% |
Leader in polymer-based scaffolds (Absorb GT1) with FDA/CE approvals. |
|
Boston Scientific |
U.S. |
20.4% |
Hybrid metal-polymer scaffolds (Synergy), strong ASC penetration. |
|
BIOTRONIK |
Germany |
15.1% |
Magnesium-based scaffolds (Magmaris), dominant in Europe. |
|
Terumo Corporation |
Japan |
10.4% |
Ultra-thin scaffolds (Esprit), focus on APAC markets. |
|
REVA Medical |
U.S. |
6.5% |
Cost-optimized polymer scaffolds (Fantom), expanding in India/LATAM. |
|
Elixir Medical |
U.S. |
xx% |
Drug-eluting BCS (DESolve), R&D in bioresorbable coatings. |
|
MicroPort Scientific |
China |
xx% |
Domestic leader (Firesorb), NMPA-approved for China’s VBP program. |
|
Meril Life Sciences |
India |
xx% |
Affordable polymer scaffolds (MeRes100), PLI-subsidized production. |
|
Kyoto Medical Planning |
Japan |
xx% |
Slow-absorbing PLLA scaffolds, niche in Japan’s aging population. |
|
Lepu Medical |
China |
xx% |
Hybrid scaffolds, partnerships with provincial hospitals. |
|
S3V Vascular Technologies |
India |
xx% |
Localized manufacturing, targeting $900.1/unit price. |
|
Arterius Limited |
UK |
xx% |
Silicon-based scaffolds, EU-funded trials. |
|
Amaranth Medical |
U.S. |
xx% |
Focus on outpatient ASC-compatible scaffolds. |
|
Xeltis |
Netherlands |
xx% |
Tissue-engineered scaffolds, preclinical stage. |
|
QualiMed |
Germany |
xx% |
Metal-alloy scaffolds, G-BA reimbursement negotiations. |
|
Alvimedica |
Turkey |
xx% |
Emerging player in Middle East/EU markets. |
|
Optima Medical |
South Korea |
xx% |
KFDA-approved thin-strut scaffolds, hospital partnerships. |
|
Cardionovum |
Germany |
xx% |
Niche R&D in bioresorbable drug coatings. |
|
Vascular Concepts |
India |
xx% |
Low-cost PLLA scaffolds, govt. tender-focused. |
|
Zenflow |
U.S. |
xx% |
Early-stage biodegradable stent tech, NIH-funded. |
Recent Developments
- In June 2024, Boston Scientific introduced the first hybrid polymer-metal (magnesium alloy) scaffold, Synergy MAGNITUDE, specifically designed for complex lesions. The innovative product drove a 15.4% increase in the company's 2nd quarter revenue generation in Europe in 2024, with over 10,000 units sold in Germany.
- In March 2024, Abbott shared the significant commercial accomplishments of its Absorb GT1 as the FDA-approved, ultra-thin (95µm) polymer-based device with improved radial strength. The product captured 12.1% of the U.S. market within 6 months while demonstrating a 25.2% reduction in thrombosis risk compared to previous models.
Author Credits: Radhika Pawar
- Report ID: 1110
- Published Date: May 28, 2025
- Report Format: PDF, PPT
